In Wednesday’s Wall Street session, Atyr Pharma Inc (NASDAQ:ATYR) shares traded at $5.14, down -4.64% from the previous session.
ATYR stock price is now 50.70% away from the 50-day moving average and 64.74% away from the 200-day moving average. The market capitalization of the company currently stands at $457.48M.
With the price target of $16, Leerink Partners recently initiated with Outperform rating for Atyr Pharma Inc (NASDAQ: ATYR). , while ‘Wells Fargo’ rates the stock as ‘Overweight’
In other news, Gross Jane A, Director bought 3,750 shares of the company’s stock on Mar 17 ’25. The stock was bought for $15,000 at an average price of $4.00. Upon completion of the transaction, the Director now directly owns 9,750 shares in the company, valued at $50115.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 04 ’25, Chief Financial Officer Broadfoot Jill Marie sold 1,254 shares of the business’s stock. A total of $4,740 was realized by selling the stock at an average price of $3.78. This leaves the insider owning 31,763 shares of the company worth $0.16 million. A total of 3.31% of the company’s stock is owned by insiders.
During the past 12 months, Atyr Pharma Inc has had a low of $1.42 and a high of $5.75. As of last week, the company has a debt-to-equity ratio of 0.17, a current ratio of 7.79, and a quick ratio of 7.79. The fifty day moving average price for ATYR is $3.4107 and a two-hundred day moving average price translates $3.120125 for the stock.
The latest earnings results from Atyr Pharma Inc (NASDAQ: ATYR) was released for 2025-03-31.
